Tumor-specific recognition molecules

• US 8,088,357 B2
• Filed: 12/01/2003
• Issued: 01/03/2012
• Est. Priority Date: 11/29/2002
• Status: Expired due to Fees

• Current Assignee: Glycotope Gmbh (Jossa Arznei GmbH)
• Original Assignee: Nemod Biotherapeutics GmbH & Co. KG
• Inventors: Goletz, Steffen, Danielczyk, Antje, Karsten, Uwe, Ravn, Peter, Stahn, Renate, Christensen, Peter Astrup
• Primary Examiner(s): CANELLA, KAREN A
• Application Number:
  US10/536,834
• Publication Number:
  US 20060251668A1
• Time in Patent Office: 2,955 Days
• Field of Search: None
• US Class Current: 424/1.49
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 47/6851 the antibody targeting a determinant of a tumour cell
• CPC Class Codes: A61K 47/6903 the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
• CPC Class Codes: A61K 51/1045 against animal or human tumor cells or tumor cell determinants
• CPC Class Codes: C07K 16/3076 against structure-related tumour-associated moieties
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/626 Diabody or triabody
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.

Claims

1. A recombinant recognition molecule comprising variable heavy (VH) and variable light (VL) antibody framework sequences and complementarity determining regions (CDRs) comprising the amino acid sequences set forth in

(i) the amino acid sequence SEQ ID NO. 1,

(ii) the amino acid sequences SEQ ID NO.2 or 3,

(iii) the amino acid sequence SEQ ID NO.4, 5 or 6,

(iv) the amino acid sequence SEQ ID NO.7 or 8 or 9,

(v) the amino acid sequence SEQ ID NO. 10 or 11, and

(vi) the amino acid sequence SEQ ID NO. 12 or 13,

wherein the antibody framework sequences

a) FRH1, FRH2, FRH3 and FRH4 for the variable heavy chain VH are the following amino acid sequences, the amino acid position corresponding to the numbering according to Kabat:

2. A construct comprising the recombinant recognition molecules according to claim 1, further comprising (i) immunoglobulin domains of various species, (ii) enzyme molecules, (iii) signal sequences, (iv) fluorescent dyes, (v) toxins, (vi) one or more antibodies or antibody fragments with different specificity, (vii) cytolytic components, (viii) immunomodulators, (ix) immunoeffectors, (x) chelating agents for radioactive labeling, (xi) radioisotopes, and/or (xii) liposomes.

6. A method for the diagnosis, reduction, therapy, follow-up or aftercare of a core-1 positive tumor disease or a core-1 positive metastasis, comprising administering to a subject in need thereof, a construct according to claim 2.

3. A method for the diagnosis, reduction, therapy, follow-up or aftercare of a core-1 positive tumor disease or a core-1 positive metastasis, comprising administering to a subject in need thereof, a recognition molecule comprising variable heavy (VH) and variable light (VL) antibody framework sequences and complementarity determining regions (CDRs) comprising the amino acid sequences set forth in

(i) the amino acid sequence SEQ ID NO. 1,

(ii) the amino acid sequences SEQ ID NO.2 or 3,

(iii) the amino acid sequence SEQ ID NO.4, 5 or 6,

(iv) the amino acid sequence SEQ ID NO.7 or 8 or 9,

(v) the amino acid sequence SEQ ID NO. 10 or 11, and

(vi) the amino acid sequence SEQ ID NO. 12 or 13,

and which specifically binds to the core 1 antigen.

4. The method according to claim 3, wherein the recognition molecule is a non-labeled recognition molecule, which is an IgM or IgG or is a molecule derived therefrom.

5. The method according to claim 3, wherein the recognition molecules are multibody.